Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05290558
Other study ID # 2020/2019
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 7, 2022
Est. completion date December 31, 2024

Study information

Verified date August 2022
Source KK Women's and Children's Hospital
Contact Tat Xin Ee, MD
Phone 97717807
Email ee.tat.xin@singhealth.com.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the safety and efficacy of Bu Shen Yi Jing (BSYJ) Pill , a type of traditional Chinese medicine, in improving male subfertility and semen parameters.


Description:

Subfertility is defined as a failure to conceive after 1 year of regular unprotected intercourse. Impaired fertility affects 10 to 15% of couples and male factor is the cause of subfertility in 25 to 40% of couples. With increasing paternal age, semen volume, sperm motility and the percentage of sperm with normal morphology decreases. The majority of men who present with subfertility have either abnormal sperm density, motility or morphology, or a combination of the above, and treatment for this condition is varied and empirical. There is a paucity of studies and randomized controlled trials to guide treatment of male factor subfertility. Various antioxidant formulations and multivitamins have been used empirically but have not been shown consistently to improve sperm counts and viability. When treatment fails, assisted reproduction will be the last resort. All assisted reproduction treatments are associated with medical, financial and emotional burden. Given the lack of proven treatment options in Western Medicine, Traditional Chinese Medicine (TCM) may provide a viable complementary treatment option. One such option is the Bu Shen Yi Jing (BSYJ) pill. A clinical observational study conducted by the team in Singapore Thong Chai Medical on subfertile male patients with poor sperm quality and a body constitution of Kidney Deficiency showed that 2 courses of BSYJ pill over a 6 months' duration resulted in successful conception of 33% of azoospermic male patients (n = 60). In a subgroup of patients where serial sperm analysis was available (n=10), the percentage of sperm with grade A motility increased from a median of 22.6 ± 2.4% pre-treatment to 35.1 ± 3.2% post treatment (p < 0.05); and the hyaluronic binding assay improved from 33.2 ± 2.4% to 72 ± 4.6% (p < 0.05). This suggests that BSYJ pills possibly works on improving the motility of the sperms in patients having the Kidney deficiency body constitution. As such, this study aims to validate these hypotheses and anecdotal evidence by conducting a safety and efficacy study of the BSYJ pill on a prospective cohort.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender Male
Age group 21 Years to 49 Years
Eligibility Inclusion Criteria: - Duration of subfertility (both primary and secondary) = 1 year; - Any or combination of the three abnormal semen parameters, defined according to the 2010 WHO criteria, including - Oligozoospermia, with sperm concentration less than 15 x 10^6, - Teratozoospermia, with normal sperm morphology less than 4%, and - Asthenozoospermia, with total sperm motility less than 40%, or progressive sperm motility less than 32%. - Diagnosed with TCM syndrome of Kidney Deficiency Based on a prominent TCM diagnosis textbook known as TCM Diagnostics, the main symptoms patients need to fulfil for Kidney Deficiency are either nocturnal polyuria or lower back pain. In addition, patients need to fulfil any 1 of the secondary symptoms, including fatigue; dizziness; tinnitus or deafness; memory loss; excessive urination; low libido; wet dreams; premature ejaculation; presence of feverish palms and soles or night sweats; dry mouth or throat; cold intolerance or preference for warmth; poor sleep quality. Presence of both 1 main symptom and 1 secondary symptom allows for the diagnosis of the Kidney Deficiency syndrome. Patients who meet all three criteria mentioned above will be included in the study. Exclusion Criteria: - Azoospermia and severe oligoasthenoteratozoospermia; - Aspermia; - Varicocele; - Recent urogenital infections; - Y chromosome deletions; - Abnormal karyotypes - History of chemotherapy and / or radiotherapy; - Patients on fertility supplements or supplements marketed to improve fertility; - Patients with uncontrolled diabetes or/and hypertension; with uncontrolled chronic medical conditions - Patients currently already on BSYJ pills treatment

Study Design


Intervention

Drug:
Bu Shen Yi Jing Pill
Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae. Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Placebo Drug
Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule. Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year

Locations

Country Name City State
Singapore KK Women's and Children's Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
KK Women's and Children's Hospital

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other To assess the common side effects of the BSYJ pill Participant reported symptoms of excessive heat syndrome such as ulcers and mouth dryness. 1 year
Other To assess the common gastrointestinal side effects of the BSYJ pill Participant reported symptoms of gastrointestinal symptoms such as indigestion and appetite reduction. 1 year
Other To evaluate safety profile of BSYJ pill Participants will be assessed frequently to pick up any side effects noted after commencement of BSYJ pill Up to 1 year after recruitment
Other Change from baseline severity based on TCM symptom scoring questionnaire As BSYJ pills target the TCM syndrome of Kidney Qi deficiency, symptoms related to Kidney Qi deficiency syndrome, which includes frequent urination and back pain, fatigue and dizziness, may be improved through this research. 1 year
Other Number of participants with improvement in TCM syndrome of Kidney Qi deficiency from baseline according to the TCM symptom scoring questionnaire Stagnation As BSYJ pills target the TCM syndrome of Kidney Qi deficiency, symptoms related to Kidney Qi deficiency syndrome, which includes frequent urination and back pain, fatigue and dizziness, may be improved through this research. 1 year
Other Patient's basic demographics Defined by age, ethnicity, marital status 1 year
Other Patient's partner's basic demographics Defined by age, ethnicity, marital status 1 year
Other Patients's anthropometry Defined by height, weight and body mass index based on weight (kg) /height (m)2 1 year
Other Number of participants who smoke Self-reported 1 year
Other Number of participants who take alcohol regularly Self-reported based on the amount and frequency of alcohol intake 1 year
Other Number of participants who have dietary restrictions Self-reported 1 year
Other Number of participants with occupational exposures to chemicals Self-reported 1 year
Other Number of participants with exposure to hot baths or jacuzzi Self-reported 1 year
Other Number of participants who uses recreational drugs Self-reported 1 year
Other Number of participants who exercise regularly Self-reported 1 year
Other Number of patients with significant medical history Self-reported details of medical history 1 year
Other Number of patients with significant surgical history Self-reported details of surgical history 1 year
Other Number of patients on regular medications Self-reported details of types of regular medications 1 year
Other Number of patients with drug allergies Self-reported details of drug allergies 1 year
Other Number of patients who take supplements Self-reported details of the type of supplements taken 1 year
Other Number of patients who take steroids Self-reported 1 year
Other Number of patients with previous history of sexually transmitted disease Self-reported details of sexually transmitted disease 1 year
Other Number of patients with previous history of genital trauma Self-reported details of genital trauma Since birth
Other Patient's fertility history Determined by the number of years of attempts at conception, sexual intercourse frequency, number of paternity (including current and/or previous partners), previous fertility treatments and medications 1 year
Other Patient's partner's fertility history Determined by the number of years of attempts at conception, sexual intercourse frequency, number of maternity (including current and/or previous partners), previous fertility treatments and medications, and menstrual history 1 year
Primary To determine the change in sperm volume from baseline after treatment with BSYJ pill From sperm samples analyses 1 year
Primary To determine the change in sperm morphology from baseline after treatment with BSYJ pill From sperm samples analyses 1 year
Primary To determine the change in sperm motility from the baseline after treatment with BSYJ pill From sperm samples analyses 1 year
Primary To determine the change in sperm concentration from the baseline after treatment with BSYJ pill From sperm samples analyses 1 year
Secondary To determine the clinical pregnancy rate and successful delivery rate after BSYJ pill Defined by the number of pregnancies and subsequent actual births after commencement of BSYJ pill 2 year
Secondary To study the safety and determine the changes in blood profile after treatment with BSYJ pill Defined by changes in participant's full blood count, renal panel, liver function test and hormone profile. 1 year
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A